Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
TETRAPHASE PHARMACEUTICALS INC (TTPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/29/2020 8-K Quarterly results
06/24/2020 8-K Quarterly results
06/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta WATERTOWN, Mass., June 22, 2020 — Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company to acquire Tetraphase for $43.0 million in cash, plus an additional aggregate amount of $16.0 million in cash potentially payable under contingent value rights to be issued in the transaction , and that on June 21, 2020 the Board determined that the La Jolla Proposal is a “Superior Offer” under the terms of the Agreement and P..."
06/05/2020 8-K Other Events
Docs: "Not Applicable"
06/04/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Not Applicable",
"Agreement and Plan of Merger by and among the Parent, the Purchaser and the Company",
"Form of Contingent Value Rights Agreement, by and between the Parent and the Rights Agent",
"Form of Support Agreement, by and among the Parent, the Purchaser and the stockholder named therein",
"Form of Exchange Agreement, by and among the Parent, the Purchaser and the holder named therein",
"Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals"
06/01/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx WATERTOWN, Mass., June 1, 2020 — Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. amending its prior proposal to acquire the Company , and has determined that the Amended Melinta Proposal is a “Superior Offer” under the terms of the Agreement and Plan of Merger, dated March 15, 2020 and amended on May 27, 2020 and on May 29, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary . In connection with this determ..."
05/29/2020 8-K Acquisition/merger/asset purchase announced
Docs: "Second Amendment to Agreement and Plan of Merger, by and among Parent, Merger Sub and Company",
"Form of Contingent Value Rights Agreement, by and between AcelRx and the Rights Agent",
"Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration WATERTOWN, Mass., May 29, 2020 — Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM to treat serious and life-threatening infections, today announced that it has entered into a second amendment to the Agreement and Plan of Merger, dated March 15, 2020, as amended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary , to increase the consideration payable to Tetraphase shareholders. Under the amended Merger Agreement, Tetraphase stockholders will receive, for each share of Tetraphase common stock, $0.5872 in cash and 0.7409 of a share of AcelRx common s..."
05/28/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx WATERTOWN, Mass., May 27, 2020 — Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. amending its prior proposal to acquire the Company , and has determined that the Amended Melinta Proposal is a “Superior Offer” under the terms of the Agreement and Plan of Merger, dated March 15, 2020 and amended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary . In connection with this determination and in accor..."
05/27/2020 8-K Acquisition/merger/asset purchase announced
Docs: "Amendment to Agreement and Plan of Merger, by and among Parent, Merger Sub and Company",
"Form of Contingent Value Rights Agreement, by and between AcelRx and the Rights Agent",
"Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration WATERTOWN, Mass., May 27, 2020 — Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline Xerava TM to treat serious and life-threatening infections, today announced that it has entered into an amendment to the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary , to increase the consideration payable to Tetraphase shareholders. Under the amended Merger Agreement, Tetraphase stockholders will receive, for each share of Tetraphase common stock, $0.2434 in cash and 0.7217 of a share of AcelRx common stock, representing approximately $1.43 in..."
05/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Not Applicable",
"Tetraphase Announces Determination of Superior Offer and Notice to AcelRx WATERTOWN, Mass., May 21, 2020 — Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline Xerava TM to treat serious and life-threatening infections, today announced that its Board of Directors has determined that the latest proposal from Melinta Therapeutics, Inc. to acquire the Company is a “Superior Offer” under the terms of the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary . In connection with this determination and in accordance with the terms of the AcelRx Merger Agreement, the Company has given notice to AcelRx of such determination and of its intention to co..."
05/21/2020 8-K Other Events
Docs: "FORM 8-K"
05/15/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
05/07/2020 8-K Other Events
Docs: "Not Applicable"
05/07/2020 8-K Quarterly results
04/28/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Promissory Note, by and between Tetraphase Pharmaceuticals, Inc. and Silicon Valley Bank, N.A",
"Promissory Note, by and between Tetraphase Pharmaceuticals, Inc. and Silicon Valley Bank, N.A"
03/16/2020 8-K Quarterly results
01/23/2020 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Secur...
Docs: "Not Applicable",
"Form of Unregistered Pre-Funded Warrant",
"Form of Unregistered Common Warrant",
"Form of Registered Pre-Funded Warrant",
"Form of Registered Common Warrant",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Form of PIPE Securities Purchase Agreement, by and among the Company and the other persons party thereto",
"Form of Registration Rights Agreement, by and among the Company and the other persons party thereto",
"Form of RD Securities Purchase Agreement, by and among the Company and the other persons party thereto",
"Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market Proceeds Will Fund the Commercialization of XERAVA WATERTOWN, Mass., January 22, 2020 - Tetraphase Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM to treat serious and life-threatening infections, today announced that it has entered into a definitive agreement with Armistice Capital, LLC, a healthcare-focused institutional investor, for the purchase, in a private placement priced at-the-market under Nasdaq rules, of 1,270,000 shares of common stock and accompanying warrants to purchase an aggregate of 1,270,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 2,063,334 shares of common stock and accompanying w..."
11/12/2019 8-K Quarterly results
10/30/2019 8-K Quarterly results
10/02/2019 8-K Quarterly results
09/30/2019 8-K Quarterly results
08/30/2019 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Payoff Letter, entered into as of August 30, 2019, by and among Tetraphase Pharmaceuticals, Inc., Solar Capital Ltd., as collateral agent and lender, and the other lenders named therein",
"Payoff Letter, entered into as of August 30, 2019, by and among Tetraphase Pharmaceuticals, Inc., Solar Capital Ltd., as collateral agent and lender, and the other lenders named therein"
08/08/2019 8-K Quarterly results
Docs: "Not Applicable",
"Tetraphase Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate Developments"
06/28/2019 8-K Quarterly results
06/12/2019 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Not Applicable",
"Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA TM Commercial Opportunity"
05/08/2019 8-K Quarterly results
Docs: "Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Corporate Developments"
03/14/2019 8-K Quarterly results
Docs: "Not Applicable",
"Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Achievements and Key 2019 Milestones"
11/08/2018 8-K Quarterly results
Docs: "Not Applicable",
"Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
11/05/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Not Applicable",
"Form of Warrant to Purchase Stock entered into in connection with the Loan and Security Agreement",
"Loan and Security Agreement, by and among Tetraphase Pharmaceuticals, Inc., Solar Capital Ltd., as collateral agent and lender, and the other lenders named therein"
09/20/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA TM for the Treatment of Complicated Intra-Abdominal Infections"
08/28/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA TM for Complicated Intra-Abdominal Infections"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy